Dose research and pharmacokinetics at PT-141 MD

The dose-finding trial

A randomized Phase 2b study in premenopausal women with female sexual dysfunction compared subcutaneous bremelanotide at 0.75, 1.25 and 1.75 mg with placebo. The 1.75 mg arm produced the most consistent improvements in sexual-function and distress scores and advanced into Phase 3. These are doses given in a study, with its own participants and oversight.

The later RECONNECT trials tested that selected dose in premenopausal women with acquired, generalized HSDD. I appreciate the development sequence for tying the figure to a question about benefit and tolerability in a defined group. An isolated quantity tells much less.

I read the selection as a clinical-development decision. It provides no personal dose calculation for someone outside the trial setting.

The prescription formulation

The FDA-approved label specifies a fixed 1.75 mg subcutaneous dose in a pre-filled single-dose device containing 0.3 mL. This page reports that formulation as part of the published record; a prescribing clinician determines whether treatment is appropriate for an individual.

The approved population is premenopausal women with acquired, generalized HSDD that is not explained by a coexisting medical or psychiatric condition, a relationship problem or a medication or substance effect. Men, postmenopausal women and sexual-performance use fall outside the approval.

The labeled quantity belongs to a particular prescription formulation.

Research-chemical material carrying the PT-141 name has no equivalent assurance of identity, purity or concentration. A label figure cannot resolve what an unverified preparation contains.

Absorption and elimination

Following the labeled subcutaneous dose, the prescribing information reports a median time to peak concentration of 1.0 hour and a mean terminal half-life of 2.7 hours, with a range of 1.9–4.0 hours. Half-life describes the decline in drug concentration; it cannot specify how long any individual will feel an effect.

The same label reports protein binding of 21%, with approximately 64.8% urinary and approximately 22.8% fecal elimination. Those figures describe the measured disposition of the drug. They leave the decision about treatment in the prescribing setting.

The oral naltrexone interaction is a useful companion to this page: how bremelanotide moves through the body and how it changes another medicine’s exposure are connected questions. A change in an existing treatment seems the more consequential question to me.

Earlier formulations

The early intranasal work in men and the subcutaneous study examined different routes during development. The eventual approved route was subcutaneous. These formulations and study populations cannot be exchanged by copying a quantity from one paper to another.

The questions about how much, by which route and alongside which medicines arrived together in development. That connection is where the subject becomes compelling for me.